<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2018-12-31">December 31, 2018</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Eriza</forename><forename type="middle">Cristina</forename><surname>Hahn</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Programa de Po ´s-Graduac ¸ão em Gene ´tica e Biologia Molecular</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul (UFRGS)</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Centro de Pesquisa Experimental do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<orgName type="laboratory">Laborato ´rio de Medicina Geno ˆmica</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Laborato ´rio de Gene ´tica Molecular</orgName>
								<orgName type="institution">Servic ¸o de Gene ´tica Me ´dica do HCPA</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Camila</forename><surname>Matzenbacher Bittar</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Programa de Po ´s-Graduac ¸ão em Gene ´tica e Biologia Molecular</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul (UFRGS)</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Centro de Pesquisa Experimental do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<orgName type="laboratory">Laborato ´rio de Medicina Geno ˆmica</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fernanda</forename><surname>Sales</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Luis</forename><surname>Vianna</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Programa de Po ´s-Graduac ¸ão em Gene ´tica e Biologia Molecular</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul (UFRGS)</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Centro de Pesquisa Experimental do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<orgName type="laboratory">Laborato ´rio de Medicina Geno ˆmica</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Brinckmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Oliveira</forename><surname>Netto</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Servic ¸o de Gene ´tica Me ´dica do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jorge</forename><surname>Villanova Biazu</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rodrigo</forename><surname>Cericatto</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jose</forename><surname>Ánto ˆnio Cavalheiro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ma</forename><surname>´rcia Portela De Melo</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlos</forename><forename type="middle">Henrique</forename><surname>Menke</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eliane</forename><surname>Rabin</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Leistner-Segal</surname></persName>
							<idno type="ORCID">0000-0003-3792-6168</idno>
							<affiliation key="aff2">
								<orgName type="department">Laborato ´rio de Gene ´tica Molecular</orgName>
								<orgName type="institution">Servic ¸o de Gene ´tica Me ´dica do HCPA</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Servic ¸o de Gene ´tica Me ´dica do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Servic ¸o de Mastologia do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Ashton-Prolla</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Programa de Po ´s-Graduac ¸ão em Gene ´tica e Biologia Molecular</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul (UFRGS)</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Centro de Pesquisa Experimental do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<orgName type="laboratory">Laborato ´rio de Medicina Geno ˆmica</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Servic ¸o de Gene ´tica Me ´dica do Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2018-12-31">December 31, 2018</date>
						</imprint>
					</monogr>
					<idno type="MD5">0099E32B32C6B028CF13A1249F61B6A5</idno>
					<idno type="DOI">10.1371/journal.pone.0209934</idno>
					<note type="submission">Received: September 12, 2018 Accepted: December 13, 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumenilike (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene.</s><s>In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G&gt;A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation.</s><s>In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%.</s><s>The current study assessed carrier frequency by genotyping TP53 c.1010G&gt;A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL.</s><s>One carrier was identified in group 1 (0.3%; CI 95% 0.1-1.76%)</s><s>and six carriers in group 2 (2.5%; CI 95% 0.93-5.39%).</s><s>The frequencies differed significantly between groups (p = 0.04).</s><s>The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL.</s><s>Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Breast Cancer (BC) is the most commonly diagnosed cancer and the leading cause of death by cancer in women, with over 2 million new cases in 2018.</s><s>In Brazil, BC incidence accounts for about 30% of all cancers diagnosed in women every year <ref type="bibr" target="#b0">[1]</ref>.</s><s>Most BC are sporadic and develop due to a combination of environmental and genetic risk factors, like low penetrance genetic variants with small effect <ref type="bibr" target="#b1">[2,</ref><ref type="bibr">3]</ref>.</s><s>However, about 10% of all BC cases, is thought to be inherited and caused by moderate or high penetrance germline mutations in cancer predisposition genes.</s><s>Although the exact molecular alteration leading to Hereditary Breast Cancer (HBC) is still unknown in about half of these cases, germline mutations in several tumor suppressor genes have been identified in association with premenopausal breast cancer, including the BRCA1, BRCA2 and TP53, among others <ref type="bibr" target="#b2">[4]</ref>.</s></p><p><s>TP53 gene encodes the p53 protein, a transcription factor with a central role in the control and regulation of events related to the cell cycle, which is activated in response to several events, including DNA damage and hypoxia <ref type="bibr" target="#b3">[5]</ref>.</s><s>Approximately 50% of solid tumors have somatic mutations in TP53, which renders it the most frequently mutated gene in different types of cancers <ref type="bibr">[6]</ref>.</s><s>Germline mutations, on the other hand, are associated with Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, autosomal dominant disorders that predispose to multiple early-onset tumors, including premenopausal BC.</s><s>In these syndromes, the estimated risk of developing at least one primary tumor by age 50 is around 80% and breast cancer is the most common solid tumor observed in adult women affected by these syndromes <ref type="bibr" target="#b4">[7]</ref>.</s></p><p><s>Germline mutations in TP53 occur at a very low frequency in the general population (1:2000-5000 individuals) <ref type="bibr" target="#b5">[8]</ref>.</s><s>However, in the Southern and Southeastern of Brazil, one specific germline TP53 mutation, c.1010G&gt;A (p.Arg337His), also known as R337H, was identified at a population frequency of 0.3%, which is much higher than any other alteration described so far in this gene <ref type="bibr" target="#b6">[9,</ref><ref type="bibr" target="#b7">10]</ref>.</s></p><p><s>The first report of the p.Arg337His mutation in Brazil was in a cohort of children with apparently isolated adrenocortical carcinoma (ACC), in which 97% were carriers <ref type="bibr" target="#b8">[11]</ref>.</s><s>In 2007, the association of the mutation with LFS/LFL was confirmed in a report of families from different Brazilian states <ref type="bibr" target="#b9">[12]</ref>.</s><s>Moreover, the mutation was identified in patients with other solid tumors of the LFS/LFL spectrum, including choroid plexus carcinoma, breast cancer and sarcomas <ref type="bibr" target="#b10">[13]</ref><ref type="bibr" target="#b11">[14]</ref><ref type="bibr" target="#b12">[15]</ref>.</s></p><p><s>Prevalence studies of this germline mutation in different BC cohorts from Southern and Southeastern Brazil have described a wide range of carrier frequencies (0.5% to 8.7%) <ref type="bibr" target="#b11">[14]</ref><ref type="bibr" target="#b12">[15]</ref><ref type="bibr" target="#b13">[16]</ref><ref type="bibr" target="#b14">[17]</ref><ref type="bibr" target="#b15">[18]</ref><ref type="bibr" target="#b16">[19]</ref><ref type="bibr" target="#b17">[20]</ref>.</s><s>Identification of TP53 p.Arg337His carriers is very important for cancer risk assessment, genetic counseling and definition of management in these individuals.</s><s>Carriers are at an increased risk for multiple tumors at an early age, often in childhood and risk reducing intervention exist.</s><s>In addition, a positive result in one individual prompts to the investigation of asymptomatic relatives, enabling proper risk management for those who carry the same variant.</s><s>In this context, the aim of the present study was to estimate TP53 p.Arg337His frequency in two groups of BC patients diagnosed in a public hospital in the State of Rio Grande do Sul (RS), in Southern Brazil, a region with high breast cancer incidence rates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participants and study design</head><p><s>This study was approved by the institutional ethics committee of Hospital de Clı ´nicas de Porto Alegre, Brazil which is recognized by the Office for Human Research Protections as an Institutional Review Board (IRB0000921).</s><s>The patients included in this study were recruited from the Mastology and Medical Genetics Services of Hospital de Clı ´nicas de Porto Alegre (HCPA), a public general and university hospital in the State of RS, Southern Brazil.</s><s>Patients were recruited and analyzed in two separate groups.</s><s>Patients of the first group were enrolled between 2002 and 2010 and the only inclusion criteria were a histologically proven diagnosis of breast cancer at or above age 18 years and willingness to participate in the study.</s><s>At inclusion, patients were not selected regarding FH of cancer and hence, this group will be described as the "unselected" group or group 1.</s><s>The second group analyzed, included 239 women diagnosed with breast cancer at or below age 45 years, who did not have Chompret criteria indicative for TP53 mutation testing <ref type="bibr">[21]</ref>.</s><s>This group will be described as the "early-onset BC" group or group 2. The 45-year age limit was adopted to stratify groups in relation to age at BC diagnosis, since this cutoff is commonly used in LFS studies and also in guidelines that indicate TP53 mutation testing (i.e.</s><s>National Comprehensive Cancer Network-NCCN, Chompret criteria) <ref type="bibr">[21]</ref>.</s><s>The study was approved by the institutional ethics committee of Hospital de Clı ´nicas de Porto Alegre, Brazil and all patients provided written informed consent (protocol numbers 2004-0438 and 2014-0658).</s><s>Demographic, clinical and family history data were obtained by review of medical records.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genotyping</head><p><s>Genomic DNA was obtained from the leukocyte fraction of peripheral blood, using the Salting-out methodology or the commercial kit Flexigene (Qiagen) <ref type="bibr" target="#b18">[22]</ref>.</s><s>In one of the mutation carriers (unselected group) tumor samples were available and loss of heterozigosity (LOH) was evaluated in DNA from the breast tumor.</s><s>To this end, a pathologist prepared and analyzed HE slides containing slices of the tumor sample.</s><s>Next, a BC region was delineated, microdissected and used for DNA extraction with the commercial kit ReliaPrep FFPE gDNA Miniprep System (Promega).</s></p><p><s>Germline mutation screening and tumor tissue analysis were performed by allelic discrimination using a TaqMan assay, with customized probes for the wild-type (c.1010G)</s><s>and mutant (c.1010A) alleles.</s><s>In all samples with a mutant allele, genotyping was confirmed by Sanger sequencing, as described by <ref type="bibr" target="#b12">Giacomazzi et al. 2014</ref>.</s><s>Assessment of the haplotype associated with the mutant allele was done as described by Garritano et al 2010.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The mutation frequency was obtained by simple counting of the number of patients with at least one mutated allele.</s><s>Clinical and family history data of the two groups were compared by Chi-Square Test.</s><s>Confidence Intervals of the mutation frequency were estimated using Win-Pepi Software (version 11.65).</s><s>Comparisons of mutation prevalence data between groups was done using Fisher's Exact Test.</s><s>Values of p&lt;0.05 were considered as a statically significant result.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Demographic and clinical data</head><p><s>Demographic and clinical data of the two groups of patients studied are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>In both groups, women account for more than 99% of the sample.</s><s>Mean age at BC diagnosis was 56.3 years (SD: 13.1 years, range: 28-89 years) in group 1 and 36.7 years (SD: 5.3 years, range: 23-45 years).</s><s>In group 1, most patients were diagnosed after age 45 years (74.9%)</s><s>and, regarding FH of cancer, 62.2% of the participants reported a positive FH of cancer, considering report of at least one 1 st , 2 nd or 3 rd -degree relative with cancer, without, necessarily, being compatible with a history of predisposition to hereditary cancer syndromes or fulfilling the established clinical criteria for TP53 mutation testing (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The most common histological BC type was invasive ductal carcinoma (72.4%).</s></p><p><s>TP53 p.Arg337His frequency in the unselected group was 0.3% (1/315-95% CI: 0.01-1.76%),</s><s>equivalent to that observed in the general population of the Southern and Southeastern regions of Brazil.</s><s>The only carrier identified was from a small city from the State of São Paulo, reported Portuguese ancestry, positive family history of cancer and showed the same haplotype previously described as founder haplotype <ref type="bibr" target="#b19">[23]</ref>.</s><s>She was diagnosed with an invasive ductal carcinoma of the breast (hormone receptor negative, HER2-positive, overexpressing p53) at age 67 years.</s><s>At age 69 years, the proband was diagnosed with a gastric adenocarcinoma, and died shortly thereafter.</s><s>Genotyping of the breast tumor did not reveal loss of heterozygosity in the tumor.</s></p><p><s>In the second group of patients analyzed, 6 carriers were identified (6/239; 2.5%, 95% CI: 0.93-5.38%),</s><s>all with the founder haplotype.</s><s>Tumors samples were not available for mutation testing and assessment of LOH.</s><s>The carrier frequencies between groups differed significantly (p = 0.04).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>By now, several studies have provided evidence that the germline TP53 mutation p.Arg337His is present at an exceedingly high frequency in the general population from Southern and Southeastern Brazil.</s><s>Although penetrance of this oligomerization domain mutant seems to be decreased in relation to DNA-binding domain mutations, its populational frequency is unsurpassed by any other cancer predisposing germline mutation <ref type="bibr" target="#b6">[9,</ref><ref type="bibr" target="#b7">10,</ref><ref type="bibr" target="#b20">24]</ref>.</s><s>Carrier families have different phenotypes, showing either very few or simplex cancer cases or more complex family histories ranging from phenotypes not clearly suggestive of LFS/LFL to phenotypes typical of these syndromes.</s><s>In p.Arg337His families, breast cancer is the most common solid tumor diagnosed in adult carriers and its diagnosis can occur at different ages <ref type="bibr" target="#b6">[9,</ref><ref type="bibr" target="#b12">15,</ref><ref type="bibr" target="#b20">24]</ref>.</s><s>The understanding of genetic factors related to BC is essential, because its incidence is increasing worldwide, with varying mortality rates: developed countries tend to present a reduction, while developing countries show increasing rates, a trend also observed in Southern Brazil <ref type="bibr" target="#b21">[25,</ref><ref type="bibr" target="#b23">26]</ref>.</s><s>In Porto Alegre, the capital that proportionally shows the highest BC incidence rate in the country, an important proportion of women is hospitalized or die from BC before 50 years of age <ref type="bibr" target="#b25">[27,</ref><ref type="bibr" target="#b26">28]</ref>.</s><s>A population-based study carried out in the city of Porto Alegre with more than 9,000 participants, revealed that 6.2% of women visiting primary health care units presented a phenotype compatible with HBC, and of these, approximately 70% met criteria for LFS or LFL <ref type="bibr" target="#b27">[29]</ref>.</s><s>From these numbers, one could hypothesize that the TP53 p.Arg337His mutation is an important contributor to the BCrelated burden in the region.</s></p><p><s>In BC, age at diagnosis is an important point to consider.</s><s>In LFS and LFL, several studies have described a higher mutation prevalence among women with pre-menopausal when compared to post-menopausal breast cancer and phenotypic criteria that suggest the syndrome (i.e.</s><s>Chompret criteria) use the age of 45 years as a cutoff age for breast cancer diagnosis <ref type="bibr" target="#b12">[15]</ref>.</s><s>In the current study, we have analyzed two groups of patients.</s><s>In the unselected group of women with breast cancer, recruited regardless of age at cancer diagnosis and cancer family history, carrier frequency was equal to that observed in the general population.</s><s>This was quite surprising, since one would expect a slightly increased prevalence.</s><s>However, a previous study comprising 390 BC patients-that were also not selected regarding FH-revealed a similar prevalence to that seen in the unselected group of the present study, 0.5% <ref type="bibr" target="#b15">[18]</ref>.</s><s>In this group, mean age at BC diagnosis (56.3 years), and the proportion of women diagnosed after 45 years (almost 75%), may have influenced mutation prevalence.</s><s>Carrier frequency in the second group of patients (diagnosed at or below 45 years who were recruited from a cancer genetics clinic and did not have criteria for TP53 mutation testing) was 2.5% similar to mutation prevalences observed in 2 previous studies that included women with a FH compatible with hereditary breast and ovarian cancer syndrome, 0.94% and 2.5% <ref type="bibr" target="#b16">[19,</ref><ref type="bibr" target="#b17">20]</ref>.</s><s>Taken together, these findings suggest that a BC diagnosis below age 46 years is an important indicator of TP53 p. Arg337His presence.</s></p><p><s>Provided that the carrier frequency among women with breast cancer &lt;46 years without a family history is 2.5%, the next question is whether this prevalence justifies routine mutation testing in such cases.</s><s>In the Ashkenazi Jewish population, where founder BRCA1 and BRCA2 mutations are present in about 2.5% of the individuals, cost-effectiveness studies have implied that population testing is justified <ref type="bibr" target="#b28">[30]</ref>.</s><s>On the other hand, for more complex and admixed populations, where no BRCA founder mutations exist and mutation prevalence is around 0.25%, several authors have stated that population testing is not cost-effective and therefore not justified <ref type="bibr" target="#b29">[31,</ref><ref type="bibr" target="#b30">32]</ref>.</s></p><p><s>Additional studies with larger samples of patients should be undertaken to provide definitive carrier frequencies in different clinical scenarios.</s><s>However, the present study, provides further arguments to suggest a role for mutation testing of all women diagnosed with BC below age 46 years in Southern Brazil.</s><s>A better understanding of the penetrance and the costeffectiveness of TP53 p.Arg337His testing in women with pre-menopausal breast cancer regardless of family history criteria could contribute to determine if such testing is justified from a public health care perspective.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Demographic and clinical data of the "unselect group"-group 1 and "early-onset BC"-group 2).</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Group 1</cell><cell></cell><cell>Group 2</cell><cell>p (chi-square test)</cell></row><row><cell></cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell><cell></cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>313</cell><cell>99.3</cell><cell>237</cell><cell>99.2</cell><cell>0.78</cell></row><row><cell>Male</cell><cell>2</cell><cell>0.7</cell><cell>2</cell><cell>0.8</cell><cell></cell></row><row><cell>Age at breast cancer diagnosis (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>�45</cell><cell>70</cell><cell>22.2</cell><cell>239</cell><cell>100.0</cell><cell></cell></row><row><cell>�46</cell><cell>236</cell><cell>74.9</cell><cell>-</cell><cell>-</cell><cell></cell></row><row><cell>Not specified</cell><cell>9</cell><cell>2.9</cell><cell>-</cell><cell>-</cell><cell></cell></row><row><cell>Mean, SD</cell><cell>56.3, 13.1 years</cell><cell></cell><cell>36.6, 5.3 years</cell><cell></cell><cell>&lt;0.0001 (t test)</cell></row><row><cell>Additional primary tumors</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>34</cell><cell>10.8</cell><cell>23</cell><cell>9.6</cell><cell>0.429</cell></row><row><cell>No</cell><cell>255</cell><cell>81.0</cell><cell>216</cell><cell>90.4</cell><cell></cell></row><row><cell>Not specified</cell><cell>26</cell><cell>8.2</cell><cell>-</cell><cell></cell><cell></cell></row><row><cell>Personal history of cancer (other tumors)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Breast</cell><cell>14</cell><cell>41.1</cell><cell>16</cell><cell>69.7</cell><cell>0.106</cell></row><row><cell>Endometrial</cell><cell>9</cell><cell>26.5</cell><cell>1</cell><cell>4.3</cell><cell></cell></row><row><cell>Colorectal</cell><cell>2</cell><cell>5.9</cell><cell>1</cell><cell>4.3</cell><cell></cell></row><row><cell>Others</cell><cell>9</cell><cell>26.5</cell><cell>5</cell><cell>21.7</cell><cell></cell></row><row><cell>Family History of Breast Cancer</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>95</cell><cell>13.7</cell><cell>139</cell><cell>58.2</cell><cell>&lt;0.001</cell></row><row><cell>No</cell><cell>177</cell><cell>30.1</cell><cell>95</cell><cell>39.7</cell><cell></cell></row><row><cell>Not specified</cell><cell>43</cell><cell>56.2</cell><cell>5</cell><cell>2.1</cell><cell></cell></row><row><cell>TP53 p.Arg337His prevalence</cell><cell>1</cell><cell>0.32</cell><cell>6</cell><cell>2.51</cell><cell>0.04 ��</cell></row><row><cell>SD: Standard Deviation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>� p&lt;0.05</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>�� Fisher´s exact test https://doi.org/10.1371/journal.pone.0209934.t001</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0209934December 31, 2018  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The study was supported by Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico (CNPq, Brazil, grant number 308829/2013-1); Fundo de Incentivo a Pesquisa (FIPE, HCPA, Brazil, project numbers 2004-0438 and 2008-0022), and Fundac ¸ão de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS, Brazil, grant number 1188-2551/13-8).</s><s>Patricia Ashton-Prolla and Sandra Leistner-Segal are researchers from CNPq (Brazil).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S1 Table. Epidemiological data collection of the study participants. (PDF)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p><s>Conceptualization: Eriza Cristina Hahn, Patricia Ashton-Prolla.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ervik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colombet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piñeros</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>cited 1 Dec</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Breast cancer risk factors. Przeglad menopauzalny = Menopause review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kamińska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ciszewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Łopacka-Szatan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miotła</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Starosławska</surname></persName>
		</author>
		<idno type="DOI">10.5114/pm.2015.54346</idno>
		<idno type="PMID">26528110</idno>
		<ptr target="https://doi.org/10.5114/pm.2015.54346" />
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="196" to="202" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The complex genetic landscape of familial breast cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Melchor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Benı</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00439-013-1299-y</idno>
		<idno type="PMID">23552954</idno>
		<ptr target="https://doi.org/10.1007/s00439-013-1299-y" />
	</analytic>
	<monogr>
		<title level="j">Human Genetics</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="845" to="863" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Unravelling mechanisms of p53-mediated tumour suppression</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Bieging</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Mello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Attardi</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrc3711</idno>
		<idno type="PMID">24739573</idno>
		<ptr target="https://doi.org/10.1038/nrc3711" />
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="359" to="370" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Malkin</surname></persName>
		</author>
		<author>
			<persName><surname>Li-Fraumeni Syndrome</surname></persName>
		</author>
		<idno type="DOI">10.1177/1947601911413466</idno>
		<idno type="PMID">21779515</idno>
		<ptr target="https://doi.org/10.1177/" />
	</analytic>
	<monogr>
		<title level="j">Genes &amp; Cancer</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="475" to="484" />
			<date type="published" when="2011">2011. 1947601911413466</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. The Lancet</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lalloo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Varley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>O'dair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pharoah</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(03)12856-5</idno>
		<imprint>
			<date type="published" when="2003">2003</date>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="1101" to="1102" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fitarelli-Kiehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Giacomazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Santos-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Graudenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rad</forename><surname>Michelli</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10689-015-9779-y</idno>
		<idno type="PMID">25564201</idno>
		<ptr target="https://doi.org/10.1007/s10689-015-9779-y" />
	</analytic>
	<monogr>
		<title level="j">Familial Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="333" to="336" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schu ¨ler-Faccini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caleffi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Miw</forename><surname>Achatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martel-Planche</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2007.10.044</idno>
		<idno type="PMID">18248785</idno>
		<ptr target="https://doi.org/10.1016/j.canlet.2007.10.044" />
	</analytic>
	<monogr>
		<title level="j">Cancer Letters</title>
		<imprint>
			<biblScope unit="volume">261</biblScope>
			<biblScope unit="page" from="21" to="25" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Ribeiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sandrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Figueiredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Zambetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Michalkiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Lafferty</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.161479898</idno>
		<idno type="PMID">11481490</idno>
		<ptr target="https://doi.org/10.1073/pnas.161479898" />
	</analytic>
	<monogr>
		<title level="j">National Academy of Sciences</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="9330" to="9335" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families</title>
		<author>
			<persName><forename type="first">Miw</forename><surname>Achatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Calvez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Martel-Planche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lopes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2005.12.039</idno>
		<idno type="PMID">16494995</idno>
		<ptr target="https://doi.org/10.1016/j.canlet.2005.12.039" />
	</analytic>
	<monogr>
		<title level="j">Cancer letters</title>
		<imprint>
			<biblScope unit="volume">245</biblScope>
			<biblScope unit="page" from="96" to="102" />
			<date type="published" when="2007">2007</date>
			<publisher>Elsevier</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Seidinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mastellaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Paschoal</forename><surname>Fortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Godoy</forename><surname>Assumpc ¸ão</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Aparecida</forename><surname>Cardinalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Aparecida</forename><surname>Ganazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1002/cncr.25826</idno>
		<idno type="PMID">21192060</idno>
		<ptr target="https://doi.org/10.1002/cncr.25826" />
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="2228" to="2235" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil</title>
		<author>
			<persName><forename type="first">J</forename><surname>Giacomazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koehler-Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Graudenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Rivero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lima</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00428-013-1439-8</idno>
		<idno type="PMID">23794094</idno>
		<ptr target="https://doi.org/10.1007/s00428-013-1439-8" />
	</analytic>
	<monogr>
		<title level="j">Virchows Archiv</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="page" from="17" to="22" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in</title>
		<author>
			<persName><forename type="first">J</forename><surname>Giacomazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Graudenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cabt</forename><surname>Osorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koehler-Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zagonel-Oliveira</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0099893</idno>
		<idno type="PMID">24936644</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0099893" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE. Public Library of Science</title>
		<editor>Brazil. Mazoyer S</editor>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e99893</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">The R337H mutation in TP53 and breast cancer in Brazil. Hereditary Cancer in Clinical Practice</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kotsopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>De Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vieira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Filho F De</surname></persName>
		</author>
		<idno type="DOI">10.1186/1897-4287-10-3</idno>
		<idno type="PMID">22455664</idno>
		<ptr target="https://doi.org/10.1186/1897-4287-10-3" />
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families. Hereditary Cancer in Clinical Practice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Cury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Ferraz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Silva</surname></persName>
		</author>
		<idno type="DOI">10.1186/1897-4287-12-8</idno>
		<idno type="PMID">24625245</idno>
		<ptr target="https://doi.org/10.1186/1897-4287-12-8" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">12</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Association of the germline TP53 R337H mutation with breast cancer in southern Brazil</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Assumpc ¸ão</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Seidinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mastellaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Ribeiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Zambetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ganti</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2407-8-357</idno>
		<idno type="PMID">19046423</idno>
		<ptr target="https://doi.org/10.1186/1471-2407-8-357" />
	</analytic>
	<monogr>
		<title level="j">BMC cancer. BioMed Central</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">357</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Lisboa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Figueiredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Torrezan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><surname>´m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Krepischi</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2350-15-55</idno>
		<idno type="PMID">24884479</idno>
		<ptr target="https://doi.org/10.1186/1471-2350-15-55" />
	</analytic>
	<monogr>
		<title level="j">BMC Medical Genetics</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">55</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population. Human Genome Variation</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Felix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Abe-Sandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Machado-Lopes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Bomfim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rsc</forename><surname>Guindalini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vcs</forename><surname>Santos</surname></persName>
		</author>
		<idno type="DOI">10.1038/hgv.2014.12</idno>
		<idno type="PMID">27081505</idno>
		<ptr target="https://doi.org/10.1038/hgv.2014.12" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>Nature Publishing Group</publisher>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">14012</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A simple salting out procedure for extracting DNA from human nucleated cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Dykes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Polesky</surname></persName>
		</author>
		<idno type="PMID">3344216</idno>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/3344216" />
	</analytic>
	<monogr>
		<title level="j">Nucleic acids research</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1215</biblScope>
			<date type="published" when="1988">1988</date>
			<publisher>Oxford University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect</title>
		<author>
			<persName><forename type="first">S</forename><surname>Garritano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gemignani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martel-Planche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Calvez-Kelm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<idno type="DOI">10.1002/humu.21151</idno>
		<idno type="PMID">19877175</idno>
		<ptr target="https://doi.org/10.1002/humu.21151" />
	</analytic>
	<monogr>
		<title level="j">Human Mutation</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="143" to="150" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Rastreamento da Mutac ¸ão R337H TP53, Diagno ´stico Precoce do Tumor de Co ´rtex Adrenal e Histo ´rico de Ca ˆncer em Famı ´lias do Estado do Parana ´</title>
		<author>
			<persName><forename type="first">Gislaine</forename><surname>Custo</surname></persName>
		</author>
		<ptr target="http://acervodigital.ufpr.br/handle/1884/30438" />
	</analytic>
	<monogr>
		<title level="m">Database: Acervo Digital UFPR</title>
				<imprint>
			<date type="published" when="2011">2011. 2017</date>
		</imprint>
	</monogr>
	<note>cited 22 Oc</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Ca ˆncer de mama: mortalidade crescente na Região Sul do Brasil entre</title>
		<author>
			<persName><forename type="first">Atc</forename><surname>Gonc ¸alves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pfc</forename><surname>Jobim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vanacor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Nunes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Albuquerque</surname></persName>
		</author>
		<author>
			<persName><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bozzetti</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1980">1980 e 2002</date>
		</imprint>
	</monogr>
	<note>Cadernos de Sau ´de Pu ´blica</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Escola Nacional de Sau ´de Pu ´blica, Fundac ¸ão Oswaldo Cruz</title>
		<idno type="DOI">10.1590/S0102-311X2007000800005</idno>
		<idno type="PMID">17653396</idno>
		<ptr target="https://doi.org/10.1590/S0102-311X2007000800005" />
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1785" to="1790" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Ana ´lise da Mortalidade por Doenc ¸as Cro ˆnicas Não Transmissı ´veis no Rio Grande do Sul</title>
		<author>
			<persName><forename type="first">L</forename><surname>Sehn</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2018-03-01">1 Mar 2018</date>
		</imprint>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Porto</forename><surname>Alegre</surname></persName>
		</author>
		<ptr target="bvsms.saude.gov.br/bvs/publica-coes/" />
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">14</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Insttituto Nacional do Ca ˆncer</title>
		<ptr target="http://www.inca.gov.br/" />
		<imprint>
			<date type="published" when="2016-10">Oct 2016</date>
		</imprint>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">Avaliac ¸ão epidemiolo ´gica da incidência e mortalidade do ca ˆncer de mama precoce no Rio Grande do Sul</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fsl</forename><surname>Vianna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Nunes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ashton-Prolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Camey</surname></persName>
		</author>
		<ptr target="https://www.lume.ufrgs.br/" />
		<imprint>
			<date type="published" when="2014">2017. 2014</date>
			<pubPlace>Porto Alegre</pubPlace>
		</imprint>
	</monogr>
	<note>Cited 18 Oc</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Palmero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caleffi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schu ¨ler-Faccini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kalakun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cbo</forename><surname>Netto</surname></persName>
		</author>
		<idno type="DOI">10.1590/S1415-47572009005000058</idno>
		<idno type="PMID">21637504</idno>
		<ptr target="https://doi.org/10.1590/S1415-47572009005000058" />
	</analytic>
	<monogr>
		<title level="j">Genetics and Molecular Biology. Sociedade Brasileira de Gene ´tica</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="447" to="455" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family historybased testing</title>
		<author>
			<persName><forename type="first">R</forename><surname>Manchanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Legood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Burnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raikou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Loggenberg</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/dju380</idno>
		<idno type="PMID">25435542</idno>
		<ptr target="https://doi.org/10.1093/jnci/dju380" />
		<imprint>
			<date type="published" when="2015">2015</date>
			<publisher>Oxford University Press</publisher>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page">380</biblScope>
		</imprint>
	</monogr>
	<note>Journal of the National Cancer Institute</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genetics in medicine: official journal of the American College of Medical Genetics</title>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><forename type="middle">E</forename><surname>Marzuillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Marco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pitini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vacchio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename></persName>
		</author>
		<idno type="DOI">10.1038/gim.2016.29</idno>
		<idno type="PMID">27906166</idno>
		<ptr target="https://doi.org/10.1038/gim.2016.29" />
		<imprint>
			<date type="published" when="2016">2016</date>
			<publisher>Nature Publishing Group</publisher>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1171" to="1180" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Yurgelun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Garber</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2015.60.8596</idno>
		<idno type="PMID">26282646</idno>
		<ptr target="https://doi.org/10.1200/JCO.2015.60.8596" />
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology: official journal of the American Society of Clinical Oncology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="3092" to="3095" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
